Evidence map›Paper›PMID 31932552›Full record

ArticleJournal of atherosclerosis and thrombosis2020

Moderate Levels of N-Terminal Pro-B-Type Natriuretic Peptide is Associated with Increased Risks of Total and Ischemic Strokes among Japanese: The Circulatory Risk in Communities Study.

Kenji Ebihara, Kazumasa Yamagishi, Mitsumasa Umesawa, Isao Muraki, Renzhe Cui, Hironori Imano, Yasuhiko Kubota, Mina Hayama-Terada, Yuji Shimizu, Tetsuya Ohira and 6 more

Abstract read
In one paragraph

Article in Journal of atherosclerosis and thrombosis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Metabolic Syndrome and Atrial Cardiomyopathy on the Risk of Stroke Mortality in the General Population.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2026
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Kenji EbiharaDepartment of Public Health Medicine, Faculty of Medicine, and Health Services Research and Development Center, University of Tsukuba.
Kazumasa YamagishiDepartment of Public Health Medicine, Faculty of Medicine, and Health Services Research and Development Center, University of Tsukuba.
Mitsumasa UmesawaDepartment of Public Health Medicine, Faculty of Medicine, and Health Services Research and Development Center, University of Tsukuba.
Isao MurakiOsaka Center for Cancer and Cardiovascular Disease Prevention.
Renzhe CuiPublic Health, Department of Social Medicine, Osaka University Graduate School of Medicine.
Hironori ImanoOsaka Center for Cancer and Cardiovascular Disease Prevention.
Yasuhiko KubotaOsaka Center for Cancer and Cardiovascular Disease Prevention.
Mina Hayama-TeradaOsaka Center for Cancer and Cardiovascular Disease Prevention.
Yuji ShimizuOsaka Center for Cancer and Cardiovascular Disease Prevention.
Tetsuya OhiraDepartment of Epidemiology, Fukushima Medical University School of Medicine.
Tomoko SankaiDepartment of Public Health and Nursing, Faculty of Medicine, University of Tsukuba.
Takeo OkadaOsaka Center for Cancer and Cardiovascular Disease Prevention.
Akihiko KitamuraOsaka Center for Cancer and Cardiovascular Disease Prevention.
Masahiko KiyamaOsaka Center for Cancer and Cardiovascular Disease Prevention.
Hiroyasu IsoDepartment of Public Health Medicine, Faculty of Medicine, and Health Services Research and Development Center, University of Tsukuba.
CIRCS Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimN-terminal pro-B-type natriuretic peptide (NT-proBNP), frequently used as a biochemical marker for detecting and monitoring heart failure, is also a risk marker for development of coronary heart disease and total stroke. However, studies that explore subtypes of ischemic stroke with regard to NT-proBNP are scarce. Here, we examined NT-proBNP and its impact upon subtypes of ischemic stroke (lacunar stroke, large-artery occlusive stroke and embolic stroke) among Japanese.

methodsWe measured NT-proBNP and categorized 4,393 participants of the Circulatory Risk in Communities Study into four groups (<55, 55-124, 125-399, and ≥ 400 pg/ml). We used a multivariable Cox proportional hazards model to examine association with risks of stroke and subtypes.

resultsDuring 4.7 years of follow-up, we identified 50 strokes, including 35 ischemic (15 lacunar, 6 largeartery occlusive, 10 embolic strokes) and 14 hemorrhagic strokes. NT-proBNP was associated with stroke risk: the multivariable hazard ratio of total strokes was 7.29 (2.82-18.9) for the highest and 2.78 (1.25-6.16) for the second highest NT-proBNP groups compared with the lowest group. The respective hazard ratios for the highest NT-proBNP group were 9.37 (3.14-28.0) for ischemic stroke and 6.81 (1.11-41.7) for lacunar stroke. Further adjustment for atrial fibrillation did not attenuate these associations. The associations were similarly observed for large-artery occlusive and embolic strokes.

conclusionWe found that even moderate serum levels of NT-proBNP were associated with the risk of total and ischemic strokes among Japanese whose NT-proBNP levels were relatively low compared with Westerners.

Indexed as

AdultAgedAged, 80 and overBiomarkersBrain IschemiaFemaleFollow-Up StudiesHumansIschemic StrokeJapanMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPrognosisSurvival RateBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)BiomarkerEpidemiologyFollow-up studyRisk factor

Identifiers

PMID31932552
PMCPMC7458784

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.